A-STAR – Innovative Research aiming to keep patients safe
The National Eczema Society is proud to be a member of the A-STAR Study Steering Group and attends regular meetings as a patient group representative.
This article was first published in the March 2022 edition of National Eczema Society’s membership magazine, Exchange.
‘A-STAR’ stands for the UK-Irish Atopic
Eczema Systemic Therapy Register. It is an observational research study assessing how well patients, children and adults with more severe atopic eczema respond to existing and new systemic treatments.
A-STAR Study
Systemic treatments include conventional immunosuppressant drugs such as azathioprine, ciclosporin and methotrexate, and the biologic drugs Dupilumab, Tralokinumab and Lebrikizumab. Now we have more drugs like JAK inhibitors (Abrocitinib, Baricitinib, Upadacitinib) as well as another new biologic waiting for their NICE approval (Nemolizumab).
Any patient who is started on or switching to one of these treatments is eligible to be enrolled in the study, provided they are seeing a dermatologist in one of the participating centres. Doctors at these centres are encouraged to approach eligible patients to take part in the study.
A-STAR records at regular intervals the disease severity, impact on people’s quality of life, and safety profiles of the different systemic treatments used in NHS clinical practice. This data is especially useful when people are taking these treatments for longer periods of time. It is hoped this information will help doctors treat people with atopic eczema more effectively in the future.
Another aim of the study is to look at the ‘real life’ cost of treating eczema, examining how much these treatments cost, compared to how well they work.
Study sites and recruitment activity so far
The A-STAR UK study was formally opened for recruitment in the summer of 2018. Since then, it has enrolled patients from 40 locations across England, Wales and Scotland.
A-STAR Ireland, led by Professor Alan Irvine (based in Dublin). The first participants from A-STAR Ireland were enrolled at St James’s Hospital Dublin, and South Infirmary – Victoria University Hospital Cork, in 2022.
There are many more sites due to open over the next few months across the UK and Ireland. To date (May 2024) over 800 patients have been recruited, both adults and children. For updates see Newsletters.
People with eczema who are starting on, or
switching to, one of these systemic treatments are eligible to be enrolled in this study, provided they are being treated by a dermatologist in one of the participating centres. Doctors at
these centres are encouraged to approach eligible patients to take part in the study.
To find out more about involvement see Participants – A-STAR (astar-register.org).
A-STAR bio – Moving Towards Personalised Medicine
There is increasing recognition that atopic eczema is a highly complex condition with multiple causes and pathways. As well as the observational data collection, A-STAR also has an embedded Bioresource that is being set up at a limited number of existing centres. Participants have the option of giving blood and other tissue samples. A-STAR analyses DNA through these samples to understand why participants are more likely to suffer from eczema and also why they respond better or worse to a specific treatment. This should lead to a more personalised approach in treating atopic eczema in the future.
For more information about A-STAR, please do visit the A-STAR website.